🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Management of Adult Acute Lymphoblastic Leukemia : A review jamanetwork.com/journals/jamao… #leusm

Thanks 🙏 to The ASCO Post ASCO for featuring our #Pivekimab #PVEK #CD123 for #BPDCN program | Naveen Pemmaraju, MD Naval Daver, M.D. MD Anderson Cancer Center | #endcancer ascopost.com/news/june-2025…

The 2025 European Hematology Association Congress is less than a week away! To prepare for the meeting, check out the top abstracts to watch, with insights from Naval Daver, M.D., Aaron Gerds MD, MS, and Tycel Phillips #lymsm #leusm #oncology onclive.com/view/experts-u…

Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory neurotoxicity syndrome neurotoxicities. ow.ly/blvf50W5eJA #clinicaltrialsandobservations #immunobiologyandimmunotherapy

👉👉👉Wonderful to attend our Thirteenth Annual Leukemia Fellowship Graduation 👨‍🎓 to celebrate our amazing MD Anderson Cancer Center Leukemia Fellows !! Hagop Kantarjian,MD G Garcia-Manero Tapan Kadia #leusm #endcancer

👉👉👉Spectacular moment celebrating 🙏 our wonderful graduating Leukemia Fellows together yesterday evening ! MD Anderson Cancer Center #leusm #endcancer Hagop Kantarjian,MD G Garcia-Manero Tapan Kadia

👉👉 Happy to share results of investigator initiated trial of Ruxolitinib in Ph-Like ALL. We did not see any significant responses in R/R adult Ph-like B-ALL with ruxolitinib. 👉Looking back at my emails Marina Konopleva and I had initial discussions with Incyte for this trial at ASH

👉 Check the Top #AML #abstracts at #EHA2025 by date and ID Many presented by our #Leukemia Faculty & Fellows from MD Anderson Cancer Center Looking forward to exciting discussions & new treatment options for patients at European Hematology Association OncoAlert AML Hub #leusm

New Approach for High-Risk MDS: BEXMAB Trial Results❗️ Bexmarilimab, a first-in-class macrophage checkpoint inhibitor, shows promising early results in combination with azacitidine for patients with high-risk myelodysplastic syndrome (HR MDS)—a group with few effective options,

Join us at the 4th Annual AML-ALL EU Focus Meeting in Athens, Greece. Spend two days exploring the evolving treatment landscape of AML and ALL—addressing practical questions on MRD, transplant decisions, CAR-T integration, and frontline care alongside global hematology leaders.

#TBT to an unforgettable 29th Annual Winter HEME in Miami Beach! We’re already counting down to our 30th YEAR—returning this February for more insights and the latest in hematologic cancer care. 🌴Save your spot: bit.ly/4kXymAA Dr. Andre Goy Naval Daver, M.D. Ajai Chari

#EHA2025 #EHA25 Nice to meet up with Aditi Shastri, MD Naveen Pemmaraju, MD Pinkal Desai Naval Daver, M.D. at European Hematology Association meeting #leusm #MPNSM #BPDCN 🙌

stop by our poster this eve at #EHA2025 PS1620 Guillermo Montalban-Bravo will present our work on refining the Dx criteria for Oligomonocytic CMML We’ve developed a predictive model, stop by & see the details. A fantastic collaborative effort w/ Mrinal Patnaik JJ rodriguez-sevilla

This Year EHA 2025 is Doing Something New: A session Dedicated to Challenging Clinical Case Discussions - Sanam Loghavi Sanam Loghavi, MD صنم لغوی 🔬🧬 Shahram Kordasti oncodaily.com/blog/eha-2025-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews CancerWorld

#EHA25 #EHA2025 || So awesome to see our leading young superstar MDs Dr Wei Ying Jen with Dr Alex Bazinet at the posters and senior author Tapan Kadia || 🙌 #endcancer #leusm

👉👉👉 #EHA25 #EHA2025 Please join us ! Naveen Pemmaraju, MD Naval Daver, M.D. Rami komrokji | MD Education

#EHA2025 #EHA25 Wonderful job 👏 👏 👏 oral presentation at European Hematology Association by our own Musa Yilmaz, MD MD Anderson Cancer Center on DEC/VEN/QUIZ combination for patients w/ #FLT3ITD AML || Sanam Loghavi, MD صنم لغوی 🔬🧬 Naval Daver, M.D.

👉👉👉Honored to present, on behalf of my co-authors , our Ph2 findings from #CADENZA study #PVEK #CD123 for #BPDCN at #EHA25 #EHA2025 European Hematology Association | Naveen Pemmaraju, MD Naval Daver, M.D. MD Anderson Cancer Center #endcancer #leusm #BPDCN

#EHA25 #EHA2025 Thank you 🙏 #Milano 🇮🇹 for hosting us European Hematology Association | See you at #EHA2026 #EHA26 ! Claire Harrison Ruben A. Mesa, MD Nitin Jain Naval Daver, M.D. Joshua Zeidner MD Aditi Shastri, MD

Treatment with bexmarilimab has already shown favorable efficacy among patients with relapsed/refractory MDS who experienced progression following a hypomethylating agent. #heme | Naval Daver, M.D. hubs.li/Q03sxrSn0